The Swiss Market Index was 0.23% in the red on Wednesday's close as investors took stock of the latest private sector and economic data prints that hit the market, alongside corporate updates.
The Swiss parliament's upper house voted in favor of the proposed new capital requirements for UBS Group (UBSG.SW), requiring the banking group to back its foreign subsidiaries with 90% common equity Tier 1 capital. UBS shares ended the trading day 1.71% lower.
"If the decision by the Council of States is confirmed, UBS would be required to hold a total of around USD 33bn of incremental CET1 capital since the acquisition of Credit Suisse," the group said in response to the Council of States' decision. "This political outcome is not a compromise and fails to address the root causes of the Credit Suisse collapse ... As the parliamentary process continues, UBS will focus on protecting its long-term interests. UBS will also continue to contribute facts and analysis to support informed decision-making and advocate for regulation that is truly targeted, proportionate and internationally aligned."
Meanwhile, Roche (RO.SW) reported that interim results from the phase 3 Imagination study for once-monthly sefaxersen in adults with progressive kidney condition primary IgA nephropathy, or Berger's disease, met its primary endpoint of statistically significant and clinically meaningful proteinuria reduction at 37 weeks, compared with placebo. The investigational subcutaneous injection's safety and tolerability profile was also observed to be in line with previously reported data. The Swiss pharmaceutical giant's stock was flat at closing.
Outside Switzerland and in other news, the seasonally adjusted S&P Global Flash Eurozone Composite PMI Output Index rose to a 41-month high of 53.1 in September from 52 in August. The provisional reading marks the third straight month of business activity expansion in the euro area.
The Organisation for Economic Co-operation and Development lifted its 2026 economic growth forecasts for the euro area and the UK by 0.2 percentage points each to 1% and 1.1%, respectively, compared with its June estimates, according to its latest Economic Outlook report. The OECD also edged up its global gross domestic product growth projection by 0.1 percentage point to 2.9% in 2026, noting that continued uncertainty regarding the evolution of the Middle East conflict remains a key risk to its outlook.